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abstract: Cyclic adenosine monophosphate (cAMP) controls differentiation in several types of cells during brain develop-
ment. However, the molecular mechanism of cAMP-controlled differentiation is not fully understood. We investigated the 
role of protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac) on cAMP-induced glial fibrillary 
acidic protein (GFAP), an astrocyte marker, in cultured glial cells. B92 glial cells were treated with cAMP-elevating drugs, an 
activator of adenylate cyclase, phosphodiesterase inhibitor and a ß adrenal receptor agonist. These cAMP-elevating agents 
induced dramatic morphological changes and expression of GFAP. A cAMP analog, 8-Br-cAMP, which activates Epac as well 
as PKA, induced GFAP expression and morphological changes, while another cAMP analog, 8-CPT-cAMP, which activates 
Epac with greater efficacy when compared to PKA, induced GFAP expression but very weak morphological changes. Most 
importantly, the treatment with a PKA inhibitor partially reduced cAMP-induced GFAP expression. Taken together, these 
results indicate that cAMP-elevating drugs lead to the induction of GFAP via PKA and/or Epac activation in B92 glial cells.
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introduction
It was recently shown that cyclic adenosine mono-
phosphate (cAMP)-elevating stimuli, including pitu-
itary adenylate cyclase-activating polypeptide, lead 
to astrocytic differentiation of cortical precursors in 
rat [1]. Thus, while cAMP might play an essential 
role in regulating astrocytic differentiation [2-6], the 
signaling pathway of this cAMP-induced astrocytic 
differentiation remains unknown.
cAMP is a second messenger molecule that medi-
ates signal transduction initiated by ligand binding 
to G-protein-coupled receptors such as adrenergic 
receptors. Pharmacological manipulation of cyclo-
nucleotide phosphodiesterases (PDEs), which degrade 
cAMP, and adenylate cyclase (AC), which produces 
cAMP, provides a powerful strategy for understanding 
the biological processes relayed by this intracellular 
second messenger [7,8].
Intracellular cAMP is thought to be a widespread 
regulator of physiological responses [7-9]. cAMP reg-
ulates many physiological responses via different mo-
lecular players, including protein kinase A (PKA) and 
exchange protein directly activated by cAMP (Epac) 
[3,7,8,10-12]. We have reported that cAMP regulates 
cell proliferation, apoptosis and inflammation via 
Epac and/or PKA [13,14].
In this study, we established that intracellular 
cAMP elevation induced morphological changes via 
PKA and astrocyte marker expression via PKA and/
or Epac activation in B92 glial cells.
Materials and Methods
chemicals
Forskolin (Fsk), isobutylmethylxanthine (IBMX) 
and isoproterenol (ISO) were purchased from Wako 
Pure Chemical Industries, Ltd. (Osaka, Japan). 
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8-(4-chlorophenylthio)-2-O-methyladenosine-3’,5’-
cyclic monophosphate sodium salt (8-CPT-cAMP) 
and 8-bromoadenosine-3’,5’-cyclic monophosphate 
(8-Br-cAMP) were purchased from Biaffin GmbH & 
Co KG (Kassel, Germany). H89 and tetramethylrho-
damine isothiocyanate (TRITC)-labeled phalloidin 
were purchased from Calbiochem (La Jolla, CA) and 
Sigma-Aldrich Japan (Tokyo, Japan), respectively. 
Anti-vasodilator-stimulated phosphoprotein (VASP), 
anti-glial fibrillary acidic protein (GFAP), anti-ß actin, 
horseradish peroxidase (HRP)-linked anti-mouse IgG 
and anti-rabbit IgG antibodies were obtained from 
Cell Signaling Technology, Inc. (Beverly, MA). Anti-
phospho-specific VASP (Ser157) antibody and donkey 
anti-mouse IgG H&L (Alexa Fluor® 488) were pur-
chased from Calbiochem and Abcam (Cambridge, 
UK), respectively. Dulbecco’s modified Eagle’s me-
dium (DMEM) and fetal bovine serum (FBS) were 
purchased from Wako Pure Chemical Industries, Ltd. 
and Invitrogen (Carlsbad, CA), respectively.
cell culture
B92 rat glial cells were a gift from Prof. Ohno-Shosaku 
(Kanazawa University). The cells were cultured in 
DMEM with 10% FBS at 37ºC in a 5% CO2 incubator. 
actin filament and gfaP staining
To evaluate the actin cytoskeletons and GFAP expres-
sion, the cells were fixed in 3.7% (v/v) formaldehyde 
in Dulbecco’s phosphate-buffered saline, permeabi-
lized in 0.25% Triton X-100 and blocked with 3% nor-
mal goat serum [15]. F-actin and GFAP were visual-
ized by TRITC-labeled phalloidin and Alexa Fluor® 
488-labeled antibody, respectively, using an inverted 
fluorescence microscope EVOS (Life Technologies, 
Tokyo, Japan).
elongated cell counts
Cells were photographed under a microscope, and 
three randomly selected fields (using a 10x objective 
lens) from each culture dish (n=3) were captured for 
quantification.
rt-Pcr
Total RNA was isolated using the FastPure RNA Kit 
(Takara, Tokyo, Japan). cDNAs were synthesized from 
1 µg total RNA using the PrimeScript II 1st strand 
cDNA Synthesis Kit (Takara). PCR-based specific gene 
amplification for GFAP and ß actin was performed 
with LA Taq (Takara). The PCR conditions were 35 
cycles of amplification (30 s at 94°C; 30 s at 55°C; 30 
s at 72°C) or 25 cycles of amplification (30 s at 94°C; 
30 s at 60°C; 30 s at 72°C) for GFAP or ß actin, re-
spectively. The following primers were used for GFAP, 
forward: 5’-GAT GAT GGA GCT CAA TGA CCG-3’, 
reverse: 5’-CAG CCT CAG GTT GGT TTC ATC-3’; 
ß actin, forward: 5’-ATG GTG GGT ATG GGT CAG 
AAG-3’, reverse: 5’-CTG GGG TGT TGA AGG TCT 
CAA-3’. The PCR product were separated on a 1.9% 
agarose gel and stained with ethidium bromide.
immunoblot analysis
Immunoblotting was performed as described [13]. 
Briefly, proteins were extracted from cells and protein 
concentrations were determined using a protein assay. 
Equal amounts of protein were separated by 10% sodi-
um dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). Resolved proteins were transferred onto 
polyvinylidene fluoride (PVDF) membranes, which 
were incubated with primary antibodies (1:1000), 
followed by incubation with HRP-linked secondary 
antibodies (1:2000).
statistical analysis
The data are presented as means±SEM from at least 
three independent experiments. Statistical analysis was 
performed by ANOVA with Dunnett’s test. The results 
were considered statistically significant when p<0.05.
results
activator of adenylate cyclase promotes the 
expression of gfaP and cell morphological 
changes
B92 cells were treated with 1 μM forskolin (Fsk), an 
activator of AC. GFAP mRNA, an astrocyte marker, 
Arch Biol Sci. 2016;68(4):795-801 797
was elevated within 72 h of Fsk stimulation in B92 
glial cells (Fig. 1A and Fig. S1A). Microscopic obser-
vation revealed that Fsk regulated cell morphological 
changes, including elongation and the acquisition of 
a spindle-shape (Fig. 1B), and increased GFAP im-
munoreactivity in cells (Fig. 1C).
Phosphodiesterase inhibitor with/without ß2 
adrenal receptor agonist promotes expression of 
gfaP and cell morphological changes
B92 cells were treated only with IBMX, a PDE inhibi-
tor, or a combination of IBMX and ISO, a ß2 adrenal 
receptor agonist. The ß2 adrenal receptor is coupled 
to AC [16] and IBMX inhibits PDE, resulting in an 
increased intracellular level of cAMP. The treatment 
with IBMX (1 µM) increased the level of GFAP gene 
expression (Fig. 2A and Fig. S1B). In addition, the 
treatment with IBMX and ISO greatly increased the 
level of GFAP gene expression in comparison with 
IBMX stimulation alone (Fig. 2A and Fig. S1B). While 
VASP is a critical molecule in the regulation of ac-
tin dynamics, the increase in the level of phospho-
VASP expression points to cAMP elevation [16,17]. 
Treatment with IBMX (1 µM) increased the level of 
phospho-VASP expression (Fig. 2B and Fig. S1C). Ad-
ditionally, treatment with IBMX in combination with 
ISO greatly increased the level of phospho-VASP ex-
pression in comparison with IBMX stimulation alone 
fig. 1. Forskolin induces GFAP expression in glial cells. Changes 
in the expression of glial fibrillary acidic protein (GFAP) gene (a), 
cell morphology (b), and GFAP immunoreactivity (c) 72 h after 
treatment of B92 glial cells with forskolin (Fsk) (1 µM). White or 
black bars indicate 50 µm. Data is representative of at least three 
independent experiments.
fig. 2. IBMX and/or isoproterenol induce(s) GFAP expression 
in glial cells. Changes in the expression of GFAP gene (a) 72 h 
after treatment of B92 glial cells with only isobutylmethylxanthine 
(IBMX) (1 µM) or a combination of IBMX (1 µM) and isoproter-
enol (ISO) (1 µM). Changes in the level of phospho-vasodilator 
stimulated phosphoprotein (VASP) (b) 30 min after treatment 
of B92 glial cells with only IBMX (1 µM) or the combination of 
IBMX (1 µM) and ISO (1 µM); Changes in cell morphology (c), 
percentage of elongated cells (d), and GFAP immunoreactivity (e) 
72 h after the treatment of B92 glial cells with only IBMX (1 µM) 
or the combination of IBMX (1 µM) and ISO (1 µM). Black bar 
indicates 50 µm, white bar indicates 20 µm. Data is representative 
of at least three independent experiments. Each column represents 
the mean±SEM from three independent experiments. *P<0.05 or 
**P<0.01 vs none, #P<0.05 vs IBMX.
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(Fig. 2B and Fig. S1C). Therefore, the GFAP gene 
expression pattern correlated with the intracellular 
phospho-VASP level, indicating that astrocyte marker 
expression increased in an intracellular cAMP level-
dependent manner. Microscopic observation showed 
that the cells were dramatically extended and spindle-
shaped after both IBMX and ISO treatments (Fig. 2C, 
2D), and that GFAP immunoreactivity increased after 
stimulation with IBMX, alone or in combination of 
IBMX and ISO in cells (Fig. 2E).
caMP-promoted morphological changes and 
expression of gfaP are dependent on Pka and 
both Pka and epac, respectively, in glial cells
To examine the potential signaling role of the down-
stream effectors of cAMP, we investigated the effects 
of the non-hydrolysable cAMP analogs 8-Br-cAMP 
and 8-CPT-cAMP on the level of GFAP gene expres-
sion and cell morphology in glial cells. Both 8-Br-
cAMP and 8-CPT-cAMP upregulated the level of 
GFAP gene expression in glial cells (Fig. 3A and Fig. 
S1D), indicating that Epac contributes to GFAP gene 
expression. However, as can be seen in Fig. 3B, 8-Br-
cAMP induced morphological changes, including 
elongation and spindle shape, but 8-CPT-cAMP in-
duced very weak morphological changes compared to 
the 8-Br-cAMP. These results indicate that PKA, and 
not Epac, contributes to the morphological changes 
in the B92 cells.
Next, we examined whether the increased GFAP 
gene expression by cAMP is due to PKA activation. 
For this, we investigated the ability of the PKA in-
hibitor H89 to abrogate the IBMX-induced expression 
of GFAP mRNA. Pretreating cells with H89 partially 
blocked both PKA activation (Fig. 3C and Fig. S1E) 
and GFAP expression (Fig. 3D and Fig. S1F) by IBMX, 
indicating that cAMP-induced GFAP expression is 
partially dependent on PKA activation.
discussion
cAMP signal transduction plays a key role in the regu-
lation of cell growth and development [2,3,18,19]. The 
elevation of intracellular cAMP activates disparate 
cAMP targets, including PKA and Epac. Herein we 
describe the role of PKA and Epac in cAMP-induced 
fig. 3. cAMP analogs induce GFAP expression in glial cells. 
Changes in the expression of GFAP gene (a) and cell morphol-
ogy (b) 72 h after treatment of B92 glial cells with 8-Br-cAMP 
(0.5 mM) or 8-CPT-cAMP (1 µM). Changes in the expression of 
phospho-vasodilator stimulated phosphoprotein (VASP) (c) 30 
min after the treatment of B92 cells with only IBMX (1 µM) or the 
combination of H89 (5 µM) and IBMX (1 µM). Changes in the 
expression of GFAP gene (d) 72 h after the treatment of B92 cells 
with only isobutylmethylxanthine (IBMX) (1 µM) or the combina-
tion of H89 (5 µM) and IBMX (1 µM). Black bar indicates 50 µm. 
Data is representative of at least three independent experiments. 
8-CPT-cAMP is: 8-(4-chlorophenylthio)-2-O-methyladenosine-
3',5'-cyclic monophosphate sodium salt; 8-Br-cAMP is: 8-bro-
moadenosine-3',5'-cyclic monophosphate.
fig. 4. A proposed model for cAMP-dependent astrocyte marker 
expression and morphological changes. 8-Br-cAMP is an agonist 
of both PKA and Epac. 8-CPT-cAMP is a specific agonist of Epac. 
H89 is PKA inhibitor. PKA contributes to cAMP-induced cell 
elongation, phosphorylation of VASP, and GFAP expression. Epac 
contributes to cAMP-induced GFAP expression.
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morphological changes and increase in GFAP expres-
sion in B92 glial cells.
cAMP is an intracellular second messenger mol-
ecule that mediates many signal transduction path-
ways, including cell differentiation and morphological 
changes [2-6]. Intracellular cAMP levels are regulated 
by G-protein-coupled receptors, such as adrenergic re-
ceptors, adenylate cyclase, which produces cAMP, and 
phosphodiesterase which degrades cAMP [7,8]. In 
this study, we used pharmacological manipulations to 
increase the level of intracellular cAMP, isoproterenol 
(ISO) as a β1-adrenoreceptor agonist, forskolin (Fsk) 
as an adenylate cyclase activator and isobutylmeth-
ylxanthine (IBMX) as a phosphodiesterase inhibitor.
Elevated cellular levels of cAMP lead to the ac-
tivation of different cAMP targets, PKA and Epac. 
Activation of PKA by intracellular cAMP induces 
VASP phosphorylation. Thus, the observed increase 
in VASP phosphorylation pointed to increased lev-
els of intracellular cAMP [16,17]. We used pharma-
cological manipulations to regulate the activities of 
PKA and Epac, including cAMP analogs 8-Br-cAMP 
as both a PKA and Epac agonist, 8-CPT-cAMP as an 
Epac-specific agonist and H89 as a PKA inhibitor. We 
demonstrated the different roles of PKA and Epac on 
cAMP-induced morphological changes and increased 
GFAP expression in B92 glial cells. Our findings are 
summarized in a model presented in Fig. 4.
Interestingly, PI3K and Ca2+ were shown to play a 
role in astrocytic differentiation, including GFAP ex-
pression [20-23] and morphological changes [21,22]. 
In our previous studies, we observed that intracellular 
cAMP activates tumor suppressor protein phospha-
tase and tensin homolog deleted on chromosome 10 
(PTEN) and, in turn, induces inhibition of cell prolif-
eration via Akt deactivation in B92 glial cells, U87 gli-
oma cells and osteosarcoma cells [13,14,18]. PTEN is a 
phosphoinositide-phosphate phosphatase specific for 
the 3-position of the inositol ring [24] and a key regu-
lator of cellular PI-(3,4,5)-P3 levels. Phosphoinositide 
3-kinase (PI3K) as well as PTEN is another key regula-
tor of cellular PI-(3,4,5)-P3 (PIP3) levels. PTEN and 
PI3K have opposing effects on cellular PIP3 levels and 
consequently affect cell proliferation, survival and dif-
ferentiation through various PIP3 downstream mole-
cules, including Akt. Thus, PIP3 downstream molecule 
signal pathways are negatively or positively regulated 
by PTEN or PI3K, respectively [25,26]. Therefore, 
cAMP-activated PTEN is predicted to prevent PI3K-
mediated astrocytic differentiation in glial cells.
Liu et al. [19] have shown that cycloheximide 
induces cAMP-dependent cell differentiation in C6 
glioma cells concomitantly with cell cycle arrest, lead-
ing to inhibition of cell proliferation. Differentiation 
to acquire specific cellular phenotypes in the develop-
ing tissue coincides with the withdrawal of precursors 
from the cell cycle. Therefore, it is possible that the 
same molecules that promote cell differentiation act 
as signals to inhibit proliferation. Several reports have 
shown that PTEN regulates multiple steps in CNS de-
velopment, including astrocytic differentiation [27-
31]. Although PTEN is not a classical target of cAMP 
action, cAMP-dependent PTEN activation has been 
reported in alveolar macrophages and human glioma 
cells [32,33]. Further studies are necessary to reveal 
the role of PTEN in the relationship of GFAP expres-
sion by cAMP-elevation in B92 glial cells.
conclusions
The two families of cAMP effectors, PKA and Epac, 
regulate mechanisms for precise and integrated con-
trol of cAMP signaling pathways. PKA and Epac may 
act independently, synergistically or antagonistically 
in controlling specific cellular functions [16-18,34-38]. 
In this study, we showed that PKA and Epac contrib-
ute to cAMP-induced GFAP expression, while PKA, 
rather than Epac, is responsible for cAMP-dependent 
morphological changes. We provide insight into dif-
ferentiation through PKA and Epac downstream of 
cAMP-induced signaling in glial cells.
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fig. s1. Changes in expression of GFAP mRNA after the treatment 
with Fsk (1 µM) (a), expression of GFAP mRNA (b) and 
phospho-VASP (c) after treatment with IBMX (1 µM) or the 
combination of IBMX (1 µM) and ISO (1 µM), expression of 
GFAP mRNA after the treatment of 8-Br-cAMP (0.5 mM) or 
8-CPT-cAMP (1 µM) (d), expression of phospho-VASP (e) 
and GFAP mRNA (f) after treatment of IBMX (1 µM) or the 
combination of H89 (5 µM) and IBMX (1 µM). Each column 
represents the mean ± SEM from at least three independent 
experiments. *P<0.05 or **P<0.01 versus none, ##P<0.01 versus 
IBMX. The data can be viewed via the following link:
 www.serbiosoc.org.rs/sup/2016ABS0112FigureS1.tif
